Please assess the completion status of the following clinical trial:

Trial Title: Superb Microvascular Imaging in Focal Nodular Hyperplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with biopsy or imaging proven focal nodular hyperplasia~Exclusion Criteria:~1. Pregnant women~2. Patient's age \> 70~3. Egg allergy~4. Breast-feeding women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SMI and sonazoid (single arm) (Type: EXPERIMENTAL): Patients with focal nodular hyperplasia will undergo ultrasonography with Superb-Microvascular imaging and additional sonazoid-enhanced ultrasonography. SMI is a software function in a Toshiba Aplio 500 system. Sonazoid is contrast-material for US and it is a intervention for patient with FNH. Sonazoid will be administered at a dose of 0.015 mL/kg by manual bolus injection, followed by a 10 mL normal saline flush via a peripheral venous line

Based on this trial design, predict the completion outcome and termination type (if applicable).